ProSci

Ocrelizumab (MS4A1/CD20) Antibody, Monoclonal

Product Code:
 
PSI-10-249
Product Group:
 
Primary Antibodies
Supplier:
 
ProSci
Antibody Isotype:
 
IgG1-nd
Antibody Clonality:
 
Recombinant Antibody
Regulatory Status:
 
RUO
Shipping:
 
blue ice
Storage:
 
Store at -80˚C
1 / 1
SDS-PAGE Image
❮❯

SDS-PAGE Image

No additional charges, what you see is what you pay! *

CodeSizePrice
PSI-10-249-0.1mg0.1mg£657.00
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • Show All

Further Information

Additional Names:
2H7
Background:
Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with relapsing or primary progressive forms of multiple sclerosis. It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets the B lymphocytes that express the CD20 antigen. As a humanized molecule, ocrelizumab is expected to be less immunogenic with repeated infusions which improves the benefit-to-risk profile for patients with relapsing or progressive forms of MS.
Buffer:
PBS buffer pH7.5
Concentration:
batch dependent
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
Humanized / MS4A1/CD20 [Homo sapiens]
NCBI Organism:
homo sapiens
Purification:
>95%
Research Area:
Drug Analogues
Source:
CHO cells
User NOte:
Optimal dilutions for each application to be determined by the researcher.